Induction of a T cell mediated immune response is critical for the eradication of viral infections and tumours. Soluble peptide-loaded major histocompatibility complex-Ig ( pepÀ MHC-Ig) have been shown to bind their cognate ligands, T cell receptor, with high affinity, and are successfully used to visualize antigen-specific T cells. Furthermore, immobilized 
Introduction
The major goal of immunotherapy is to design new vaccines aimed at stimulating a protective T cell based immune response against viral infection and cancer. Generation of an effective cytotoxic T lymphocyte (CTL) immune response requires a minimum of two signals: one antigen-specific signal provided through MHC-TCR interaction and a second signal, which is provided by co-stimulatory molecules, such as CD28 on T cells and its ligand B7 family members on antigen-presenting cells (APCs). Absence of co-stimulatory signaling generally causes T cells to be in a non-responsive state such as with immature dendritic cells (DC) that express only low levels of co-stimulatory molecules. Therefore DC maturation is critical for successful T cell activation and is often accomplished through use of adjuvants that induce maturation. In a normal immune reaction activated CD4 þ T cells up-regulate CD40L, inducing maturation in CD40-expressing APC and consequently resulting in upregulation of Fcg receptors and co-stimulatory molecules such as B7 family members. It has been shown both in vitro and in vivo that cross linking CD40 on APC using anti-CD40 antibodies mature DC, bypassing the requirement of CD4 þ T cell help during the generation of CTL immune responses [1] [2] [3] [4] . While, it has been shown that short term antigen stimulation and subsequent induction of CTL responses is feasible in the absence of CD4 þ T cell help [5] [6] [7] [8] [9] [10] , CD4 þ T cell help is required to generate functional memory T cells that are capable to faster respond to antigen re-challenge [11] [12] [13] [14] . Development of soluble multivalent pepÀ MHC complexes has enabled the direct visualization of antigen-specific T cells and has significantly increased the understanding of T cell mediated immune responses. In addition, it has been shown that soluble MHC class I dimer and tetramers can be used to modulate immune responses [15] [16] [17] and activate naïve CD8 þ T cells in vitro even in the absence of co-stimulation or exogenous growth factor [18, 19] . In vivo, however, administration of multiple doses of soluble pepÀ MHC has lead to clonal exhaustion, energy or tolerance of the targeted T cells [20, 21] . One of the soluble multivalent class I MHC-Ig dimer molecules that bind their cognate T cell receptor (TCR) with high affinity has been developed in our lab. These dimeric pepÀ MHC-Ig complexes have been successfully used to visualize antigen-specific T cells [22] [23] [24] [25] . While immunological function of classical peptide antigens is dependent on uptake and reprocessing, dimeric pepÀ MHC-Ig can bind to Fcg receptors on mature APC resulting in direct T cell stimulation facilitated by anti-CD40 mAb mediated up-regulated co-stimulatory molecules. Furthermore, peptide antigens have been demonstrated to induce T cell dysfunction and deletion at antigen rich vaccination sites when administered with incomplete Freud's adjuvant [26, 27] -Ig immunization before or without anti-CD40 mAb pretreatment showed only limited expansion of adoptively transferred T cells (Fig. 1A) . Thus these findings demonstrate that maturation of APC was only effective when animals were treated with anti-CD40 mAb before pepÀ MHC-Ig immunization.
To investigate the use of pepÀ MHC-Ig to induce antigenspecific T cell immune responses in vivo in more detail, mice were adoptively transferred with SIY specific 2C T cells and 3 days later immunized s.c. with increasing amounts of SIYÀ K b -Ig (Fig. 1B) . Immunization with SIYÀ K b -Ig induced a dose dependent expansion of adoptively transferred 2C T cells, with a maximum of 18% on day 4 after immunization with the highest dose of 250 mg. In contrast no expansion of 2C T cell was observed after immunization with 250 mg non-cognate, SIINÀ K b -Ig dimer (Fig. 1B , left hand).
To provide additional T cell help through increased expression of co-stimulatory molecules on mature dendritic cells, mice were treated with anti-CD40 mAb one day prior to immunization. As shown in Figure 1B anti-CD40 mAb pretreated mice exhibited significantly higher expansion levels of the adoptively transferred cells (Fig. 1B, right hand Fig. 2A ).
Cytotoxic function of the in vivo stimulated 2C T cells was analyzed by an in vivo CTL killing assay. B6 syngeneic splenocytes were pulsed with either cognate SIY or noncognate SIIN peptide and labeled with either a high or low concentration of CFSE, respectively ( SIYÀ CFSE high , SIINÀ CFSE low ), mixed at a ratio of 1:1 and subsequently injected into B6 mice 5 days after immunization. The relative frequencies of the two CFSE labeled cell populations were determined by flow cytometry in SIYÀ K b -Ig immunized and in naïve animals to calculate specific killing in blood, spleen, draining lymph node (DN LN), and nondraining lymph node (LN) (Fig. 2B and C) . Approximately 90% specific killing was detected in all organs of the immunized mice. In contrast, no cytotoxic activity was detected against the non-cognate SIINÀ CFSE low target population and only minimal in vivo killing was observed in control animals ( Fig. 2B and C) .
Together, these data demonstrate that 
a functional immune response sufficient to kill cognate target cells.
Activation of antigen-specific CD8 þ T cells by dimeric pepÀ MHC-Ig complex is not dependent on cross presentation (Fig. 4A) . We re-challenged the immunized mice with a second pepÀ MHC dimer immunization 30 days after the initial immunization with an additional 250 mg. As expected for a memory T cell response, we observed that the secondary response was much faster than the primary response. In fact, the peak expansion for 1B2 þ /CD8 þ T cells was reached within 2 days after the boost while the primary response required 5 (data not shown). Surface staining of the 1B2 þ / CD8 þ T cells from these mice confirmed their CD44 high and CD45 low memory phenotype (Fig. 4B) . Thus dimer immunization leads to the generation of a functional antigen-specific memory T cell response in vivo that is sufficient to induce antigen-specific killing even 30 days post immunization. -Ig dimer; on day 5 after immunization we injected a mixture of SIINÀ CFSE low and SIYÀ CFSE high labeled syngeneic splenocytes and evaluated antigen-specific killing in blood, spleen, LN and DN LN 24 h later. Around 50% killing was detected in all organs investigated (Fig. 5C) . Moreover, the cytotoxic T cell response could be further augmented by increasing the amount of SIYÀ K b -Ig dimer used for immunization. Thus, as shown in Figure 5D , immunization with 1 mg instead of 250 mg of SIYÀ K b -Ig dimer resulted in an increased in vivo cytotoxicity from 50% (see Fig. 5C ) to 90% (Fig. 5D, middle bar) , which is comparable to in vivo killing in mice that were adoptively transferred with transgenic 2C T cells prior to immunization (Fig. 5D, left bar) . In contrast, no cytotoxic activity was detected in B6 mice that were adoptively transferred with 2C T cells but received no dimer immunization (Fig. 5D, right bar) . In summary these data indicate that dimer immunization has the ability to induce a functional antigen-specific T cell response from the endogenous T cell repertoire.
SIYÀ K b -Ig immunization inhibits tumour growth in vivo
The effects of pepÀ MHC-Ig immunization were also analyzed in a melanoma tumour prevention model. Wild type B6 mice were pretreated with anti-CD40 (day À17) and one day later (day À16) immunized with 250 mg/mouse -Ig immunization induces a protective endogenous T cell response that has a significant antitumour activity in a B16-SIY melanoma model.
Discussion
Over the last two decades induction of T cell immunity utilizing soluble pepÀ MHC-Ig in vivo has been a challenging approach resulting in different outcomes depending on the experimental set up and treatment protocol [15, 17, 20, 21 ].
Here we demonstrate that pepÀ MHC-Ig can be used to induce a functional antigen-specific T cell response. In a 2C T cell based adoptive transfer model utilizing cognate high affinity SIYÀ K b -Ig dimer molecules we have been able to induce a functional immune response (Fig. 1B, left half) . A single application of SIYÀ K b -Ig dimer led to a significant dose dependent increase in 2C T cell numbers with a peak at day 4-5. While previous studies by Cai et al. and others on pepÀ MHC-Ig molecules showed conflicting results regarding the requirement of co-stimulation for the expansion of 2C T cells [18, [28] [29] [30] [31] it is broadly accepted that the induction of a functional, long lasting memory CD8 þ T cell response is dependent on co-stimulation and CD4 þ T cell help [32] . It has been shown that CD8 þ T cell responses are in part regulated by CD4 mediated CD40/CD40L signalling on DC [2] [3] [4] and can be bypassed by administration of anti-CD40 mAb [33] . Consequently, pre-treatment of adoptively transferred mice with anti-CD40 mAb one day before immunization (Fig. 1A) enhanced SIYÀ K b -Ig dimer induced 2C T cell proliferation up to eightfold (Fig. 1B, right half) . Moreover, these cells were highly cytotoxic and displayed an activated phenotype (Fig. 2) .
We further investigated the mechanism of the soluble dimer immunization induced T cell response and took advantage of the fact that the clonotypic TCR of 2C T cells can recognize two different pepÀ MHC class I dimer molecules; the syngeneic MHC K b loaded with the heteroclytic peptide SIY (SIYRYYGL) and the allogeneic MHC L d with QL9 (QLSPFPFDL) that cannot be cross presented in B6 mice [19] . Our data clearly demonstrate that immunization with (Fig. 4A) . Furthermore, a re-challenge of immunized mice 30 days after the initial immunization induced a much faster T cell proliferation that peaked at day 2, hence 3 days earlier than in the initial immunization and staining with anti-CD44 and anti-CD45 proofed a CD44 high /CD45 low T cell memory phenotype (Fig. 4B ). Together these data indicated that pepÀ MHC-Ig immunization leads to the generation of a long lasting, functional memory T cell response. These findings are in line with work from Carey et al. [17] as immunization with class I pepÀ MHC-Ig and co-treatment with LPS induced a robust tumour-and virus-specific T cell response leading to reduced tumour growth and protection from lethal viral challenge. In contrast, more recently it has been found in clinical studies that vaccination with peptide and incomplete Freud's adjuvant (IFA) leads to accumulation of CD8 þ T cells at the antigen rich vaccination site and subsequent induction of T cell dysfunction and deletion [26, 27] . Thus, we see a unique advantage in class I pepÀ MHC-Ig immunization over currently used approaches to generate a fully functional memory T cell response.
We could demonstrate that successful in vitro expansion of SIY-specific T cells from immunized mice was dependent on cognate pepÀ MHC-Ig immunization (Fig. 5A and B) . In addition, we showed in an in vivo killing assay that SIYÀ K b -Ig immunized mice were able to recognize and kill SIY peptide pulsed target cells in an antigen-specific manner ( In summary, we have demonstrated that pepÀ MHC-Ig immunization together with anti-CD40 treatment induces a robust antigen-specific, cytolytic T cell response including the formation of a long lasting memory T cell population. Mechanistically we have shown that this antigen-specific T cell induction is mediated through direct TCR pepÀ MHC-Ig interaction. In addition, we have demonstrated that pepÀ MHC-Ig immunization of naïve mice can induce a protective anti-tumour response from the endogenous T cell repertoire. These studies highlight the potential of pepÀ MHC-Ig based approaches in the development of immunotherapy for cancer and infectious diseases.
Material and Methods

Mice and peptides
Eight week-old female C57BL/6 (H-2 b ; B6) mice were purchased from Jackson Laboratories (Bar Harbor, ME). 2C TCR Rag À/À transgenic mice were maintained as heterozygotes by breeding on a C57/BL6 background in the Johns Hopkins animal facilities. Heterozygous 2C males were mated to wild type B6 females. Heterozygous 2C mice were identified by flow cytometry analysis, utilizing PBMC double stained with anti-2C TCR mAb (clone 1B2 FITC) and anti-CD8 (PECy5; BD Pharmingen, San Jose, CA, USA).
Procedures involving animals and their care were in conformity with institutional guidelines that comply with national and international laws and policies. Peptides SIY (SIYRYYGL), SIIN (SIINFEKL), QL9 (QLSPFPFDL), TRP2 (SVYDFFVWL), gp100 (KVPRNQDWL), and mCMV (YPHFMPTNL) were purchased from Genscript (Piscataway, NJ).
Dimer preparation
-Ig, and L d -Ig were loaded with peptide as described previously [24] . Briefly, dimer molecules were loaded with peptide by stripping at alkaline (pH 11.5) or mildly acidic (pH 6.5) conditions and then refolded in the presence of 40-fold excess peptide and twofold molar excess of human b 2 -microglobulin [35] . Unless otherwise indicated, 
Expansion, activation and memory marker expression analysis
The 2C CD8 þ T cell in vivo expansion was analyzed according to the kinetic displayed in Figure 1 . PBMC of pepÀ MHC dimer immunized mice were double stained with anti-2C TCR-APC mAb (clone 1B2) and anti-mouse anti-CD8 FITC (BD/Pharmingen). On day 5 and 30 after dimer injection the PBMC were analyzed for activation marker expression using the following anti-mouse mAb: CD25, CD44, CD62L, CD69, and CD122. The analysis was performed on 1B2 þ /CD8 þ gated cells. Isotype controls matching to each mAb were used as negative control. All mAb used for phenotype analysis were PE labelled (BDPharmingen). Samples were read using the FACSCalibur (BD) and data analyzed by FACSExpress 3 (De Novo Software, Ontario, Canada).
In vitro killing assay
Cytotoxic activity of CD8 þ T cells was measured by 5 h 
In vivo killing assay
Target cells for the in vivo cytotoxic assay were obtained from splenocytes of naïve B6 mice, cleaned from erythrocytes by osmotic lysis, washed and split into two populations. One population was pulsed with 1 mM SIY peptide, incubated at 378C for 45 min, and labeled with a high concentration of CFSE (2.5 mM) ( SIYÀ CFSE high cells). The second control target population was pulsed with 1 mM SIIN peptide and was labeled with a low concentration of CFSE (0.25 mM) ( SIINÀ CFSE low cells) (Invitrogen, Eugene, OR). The two populations were mixed together at 1:1 ratio and i.v. injected in pepÀ MHC dimer immunized B6 mice (5 Â 10 6 /population/mouse). After 18 h the mice were sacrificed and spleen, pepÀ MHC dimer immunization site draining lymph node, and other lymph nodes were harvested. The cell suspensions obtained from each organ were analyzed by FACS for presence of two differentially CFSE labeled target populations. The recovery and percent killing of the various CFSE-labeled, peptide-pulsed target cells were calculated as follows: % of in vivo killing ¼ 100 À ([(% specific peptide pulsed cells in immunized B6/% unspecific peptide pulsed cells in immunized B6)/(% specific peptide pulsed in naïve B6/% unspecific peptide pulsed cells in naïve B6)] Â 100).
In vivo tumour inhibition experiment
On day À17 B6 mice were injected intra peritoneal (i.p.) with 10 mg/mouse anti-CD40 mAb (clone 3/23; BioLegend). One day later (day À16) mice were subcutaneously (s. . Tumour growth for each mouse was summarized as area under curve (AUC) and statistical analysis was performed in GrapPad Prism5.
